Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Oculis Holding AG - Ordinary shares (NQ:OCS)

11.43 -0.53 (-4.43%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 293,102
Open 11.79
Bid (Size) 11.00 (500)
Ask (Size) 11.99 (100)
Prev. Close 11.96
Today's Range 11.36 - 11.98
52wk Range 10.52 - 34.48
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference
From Oculis Holding AG
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire

Performance

YTD
-42.9%
-42.9%
1 Month
-2.1%
-2.1%
3 Month
-58.3%
-58.3%
6 Month
-56.0%
-56.0%
1 Year
-34.7%
-34.7%

More News

Read More
News headline image
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
Oculis Holding AG (NASDAQ:OCS) Q1 Earnings Miss Overshadowed by Key Pipeline Catalysts ↗
Via Chartmill
Topics Earnings
News headline image
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
From Oculis Holding AG
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
News headline image
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
From Oculis Holding AG
Via GlobeNewswire
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
News headline image
Trevi Therapeutics Is Up 100%, Pivotal bioVenture Adds Anyway. Here's Why That Matters. ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud
From Levi & Korsinsky, LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS
From Pomerantz LLP
Via GlobeNewswire
Which stocks are experiencing notable movement on Monday? ↗
Via Chartmill
Which stocks are moving on Monday? ↗
Via Chartmill
Monday's session: gap up and gap down stocks ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Oculis Shelves FDA Filing After Phase 3 DME Trials Miss Key Vision Goals ↗
Via MarketBeat
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Reports Q1 2026 Financial Results and Provides Company Update
From Oculis Holding AG
Via GlobeNewswire
News headline image
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
From Oculis Holding AG
Via GlobeNewswire
News headline image
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
From Oculis Holding AG
Via GlobeNewswire

Frequently Asked Questions

Is Oculis Holding AG - Ordinary shares publicly traded?
Yes, Oculis Holding AG - Ordinary shares is publicly traded.
What exchange does Oculis Holding AG - Ordinary shares trade on?
Oculis Holding AG - Ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Oculis Holding AG - Ordinary shares?
The ticker symbol for Oculis Holding AG - Ordinary shares is OCS on the Nasdaq Stock Market
What is the current price of Oculis Holding AG - Ordinary shares?
The current price of Oculis Holding AG - Ordinary shares is 11.43
When was Oculis Holding AG - Ordinary shares last traded?
The last trade of Oculis Holding AG - Ordinary shares was at 07/22/26 04:00 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.